What are exemestane and letrozole, and how are they used?
Exemestane and letrozole are both aromatase inhibitors used to lower estrogen levels in hormone-receptor positive breast cancer, typically for postmenopausal patients. They work by blocking aromatase, the enzyme that helps produce estrogen.
How do they differ: steroidal vs non-steroidal aromatase inhibition
The main practical difference is the drug class chemistry:
- Exemestane is a steroidal (type I) aromatase inhibitor.
- Letrozole is a non-steroidal (type II) aromatase inhibitor.
This can matter in tolerance and in how fully the drug shuts down aromatase activity, though both are used as standard endocrine therapy options.
How do outcomes compare when switching or choosing between them?
Clinicians often use both as endocrine backbone therapies, with choice influenced by prior treatment history, side-effect profile, comorbidities, and local guidance. Patients who do not tolerate one agent may be switched to the other, since they are different aromatase inhibitor types.
What side effects are similar, and what do patients usually report?
Both drugs commonly share aromatase-inhibitor estrogen-deprivation effects, such as:
- Joint and muscle aches (arthralgia/myalgia)
- Hot flashes
- Fatigue
- Vaginal dryness or other menopausal symptoms
They also both raise long-term concerns related to estrogen suppression, including bone thinning (osteoporosis) risk, so monitoring bone health is often part of care.
How do bone and fracture risks get managed?
Because both lower estrogen, clinicians often recommend baseline and ongoing bone health assessment (such as DEXA scanning) and consider bone-protective strategies when appropriate (for example, calcium/vitamin D and anti-resorptive therapy depending on risk).
Can one work after the other if treatment stops working?
Often, yes. If a breast cancer progresses on an aromatase inhibitor, oncologists may switch endocrine strategies, which can include changing to a different aromatase inhibitor (exemestane vs letrozole) depending on what the patient has already received and how the disease responded.
Which one is “better” for side effects like stiffness or mood?
There is no single universal winner because patients respond differently, but switching between steroidal and non-steroidal aromatase inhibitors is a common clinical tactic when adverse effects (especially musculoskeletal symptoms) are a problem.
Where do patents and drug coverage enter the decision?
If you are comparing availability and cost, patent and exclusivity status can affect which versions (brand or generics) are covered by insurance and what price you pay. DrugPatentWatch.com tracks patent-related information for branded drugs and can help you check current status. [1]
Source cited
1. DrugPatentWatch.com – Exemestane and/or letrozole patent/exclusivity tracking